Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Phase 3Active Not RecruitingNCT05814627

AbbVie487 enrolled

Overview

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is double-blinded means that neither the participants nor the study doctors will know who will be given upadacitinib and who will be given adalimumab. Study doctors put the participants in 1 of the 2 groups, called treatment arms randomly, to receive either upadacitinib or adalimumab. There is 1 in 2 chance that participants will receive adalimumab. Each group consists of 2 periods. Approximately 480 participants diagnosed with RA will be enrolled in approximately 250 sites across the world. Participants will receive the oral upadacitinib once daily and matching adalimumab placebo every other week, or the subcutaneous adalimumab every other week and matching upadacitinib placebo once daily during Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1 and will be followed for 30 days and 70 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

487

Conditions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Rheumatoid Arthritis (RA) for \>= 3 months based on the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria for RA. * Treated for \>= 3 consecutive months prior to screening with 1 tumor necrosis factor inhibitor (TNFi) (only 1 of originator or biosimilar certolizumab pegol, etanercept, golimumab or infliximab) for RA, but continue to exhibit active RA, or had to discontinue due to intolerability or toxicity, irrespective of treatment duration. Up to 15% of participants who were intolerant to 1 TNFi will be allowed to enroll. Prior administration of different biosimilar versions for the same originator TNFi or switching between originator and biosimilar version of the same originator TNFi are acceptable. Cycling between biosimilars of different originator TNF inhibitors is not acceptable. * On oral or parenteral methotrexate (MTX) therapy \>= 3 consecutive months and on a stable prescription of 15 to 25 mg/week (or \>= 10 mg/week in participants intolerant of MTX at doses \>= 15 mg/week) for \>= 4 weeks prior to the first dose of study drug. In addition, all participants should take a dietary supplement of folic acid or folinic acid throughout the study participation. * For a Chinese, Japanese, Korean, or Taiwanese participant, a stable dose of MTX \>= 7.5 mg/week is acceptable. * Additional local requirements for MTX may apply. * Meets both of the following disease activity criteria: * \>= 6 swollen joint (based on 66 joint counts) and \>= 6 tender joints (based on 68 joint counts) at screening and baseline; * High-sensitivity C-reactive protein (hsCRP) \>= 3 mg/L (central lab, upper limit of normal \[ULN\] 2.87 mg/L) at screening. Exclusion Criteria: * History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than Rheumatoid Arthritis (RA). * Prior exposure to any janus kinase (JAK) inhibitor. * Prior exposure to adalimumab (original or biosimilar) or to any approved or investigational TNF inhibitor other than infliximab, etanercept, certolizumab pegol and golimumab. * Prior exposure to an approved or investigational non-TNFi biologic disease modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease modifying antirheumatic drug (tsDMARD).

Locations (218)

AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431

Flagstaff, Arizona, United States

Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 255018

Glendale, Arizona, United States

Sun Valley Arthritis Center Ltd. /ID# 254654

Peoria, Arizona, United States

Arizona Arthritis & Rheumatology Associates - East Bell Road /ID# 253432

Phoenix, Arizona, United States

Arizona Arthritis & Rheumatology Associates - East Bell Road /ID# 255021

Phoenix, Arizona, United States

Outcomes

Primary Outcomes

Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.

Time frame: Week 12

Number of Participants with Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

Time frame: From first dose of study drug until 70 days following last dose of study drug (up to approximately 58 weeks)

Secondary Outcomes

Percentage of Participants Achieving American College of Rheumatology 50 % (ACR50) Response

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR50 response criteria: * 50% improvement in tender joint count (TJC68); * 50% improvement in swollen joint count (SJC66); and * 50% improvement in at least 3 of the 5 following parameters: * Physician's Global Assessment of Disease Activity measured on a Numerical Rating Scale of 0 to 10 (NRS) * Patient's Global Assessment of Disease Activity (NRS) * Patient's Assessment of Pain (NRS) * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

Time frame: Week 12

Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) < 2.6

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (NRS), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.

Time frame: Week 12

Change from Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP])

Time frame: Week 12

Change from Baseline in Participants Assessment of Pain

Participants indicated their level of pain over the last 7 days using the Patient's Global Assessment Pain NRS. The range is 0 to 10 with no activity being indicated by 0 and severe activity by 10.

Time frame: Week 12

Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

The HAQ-DI assesses physical function in RA. The HAQ-DI score is the average of the highest score in each of eight categories. The total score is between 0-3.0, in 0.125 increments. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment.

Time frame: Week 12

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Overview

Conditions

Interventions

Eligibility

Locations (218)

Outcomes

Primary Outcomes

Secondary Outcomes